# Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

> **NCT00185315** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 71 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Ventavis (Iloprost, BAYQ6256)

## Key facts

- **NCT ID:** NCT00185315
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2010-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185315, "Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00185315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*